About Remix Therapeutics
Reprogramming RNA Processing, Designing Therapeutic Solutions
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Watertown, MA, MA
- Founded
- 2018
- Company type
- Privately Held
Remix is working to transform patient's lives through modulation of RNA processing and addressing drug targets in diseases of high unmet medical need. We are a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages cutting-edge data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's innovative therapeutic approach led to the discovery of REM-422, a first-in-class RNA processing modulator in oncology, now being evaluated in Phase 1 clinical studies to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-MDS) and adenoid cystic carcinoma (ACC).
Company locations
100 Forge Rd, Watertown, MA, MA 02472, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
On LinkedIn
- Followers
- 10,272
- People linked to this company
- 51
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.